Glucocerebrosidase and Parkinson disease: Recent advances - Wikidata - awgldk - TriplyDB

Glucocerebrosidase and Parkinson disease: Recent advances

Glucocerebrosidase and Parkinson disease: Recent advances

http://www.wikidata.org/entity/Q27005669

about

Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease Visualization of Active Glucocerebrosidase in Rodent Brain with High Spatial Resolution following In Situ Labeling with Fluorescent Activity Based Probes Hematological manifestations and complications of Gaucher disease.Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease.A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.GBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis.Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models.Parkinson's disease dementia: Diagnostic criteria and risk factor review.Targeting glucocerebrosidase: Reduced enzymatic activity and Parkinson's disease.Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson's Disease.Heterozygous mutations of HTRA1 gene in patients with familial cerebral small vessel disease.Membrane lipids as therapeutic targets for Parkinson's disease: a possible link between Lewy pathology and membrane lipids.Current disease modifying approaches to treat Parkinson's disease.Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment.Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.The LRRK2-macroautophagy axis and its relevance to Parkinson's disease The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease.Glucocerebrosidase Mutations in Parkinson Disease.Survival and dementia in GBA-associated Parkinson's disease: The mutation matters.AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy.Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers.Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.Human Acid β-Glucosidase Inhibition by Carbohydrate Derived Iminosugars: Towards New Pharmacological Chaperones for Gaucher Disease.The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice.A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers.iPS cells in the study of PD molecular pathogenesis.Death by over-eating: The Gaucher disease associated gene GBA1, identified in a screen for mediators of autophagic cell death, is necessary for developmental cell death in Drosophila midgut.Parkinson's disease: experimental models and reality.Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study.The genetic architecture of mitochondrial dysfunction in Parkinson's disease.The Small GTPase RAC1/CED-10 Is Essential in Maintaining Dopaminergic Neuron Function and Survival Against α-Synuclein-Induced Toxicity.

P2860

Q27300869-1D1A031E-2518-4B25-B758-98F1B6ABCACF Q28074143-81CA4B38-6FB6-4CA3-B887-4F9F99AAC5A0 Q28548589-C95CE7C2-5C8F-4922-8942-94771A2118C1 Q33427535-BD40D2BC-5454-4255-A3D4-A1A8F4F05D8C Q33562458-2E027024-1ED3-4F46-99B9-0EB8C31D0C59 Q33701172-8740A02C-B2A2-4C45-B3DE-78BE2C4A3AFB Q33815765-116BFAC0-C44E-46A8-8EC8-0D20C9C5E2A4 Q34481921-4F7C7684-5808-42BE-95C6-39DA9A4369C7 Q37096051-33256331-B0D7-43CB-942B-FFB9A3CB2EEB Q37245142-FC781485-27D7-4E9B-93B1-75BA60003583 Q37462136-3D7A6C39-0CD0-4A7F-9A37-38AABEF5F1DE Q37528927-761322C6-8D84-4952-9765-9E8042C31FEC Q38270479-FC3F0F6E-5CDC-4E97-9F77-8073206CE046 Q38404712-BCF17DE9-36AC-4C80-8BD2-2D43582AAEF4 Q38564120-D4915836-559D-41EB-AF68-BB43DB192A42 Q38620227-5F9776ED-7728-49F4-837C-94F0C697F0D3 Q38637727-8F1342D4-9A25-41FC-8A98-5A35CC971615 Q38648684-5A48CFAE-03F5-4DBC-8A18-BB2D6529A4E6 Q38652153-29B3C3EE-C57F-4690-82B8-05EC6A7FB3B2 Q38727638-3B90A530-6774-4731-83E2-FDE30886933E Q38765856-F112C203-B9F3-4B8F-B23C-5203A4E03103 Q38811401-C10CBF1E-C382-457D-8EAB-536F65C3E5BA Q38927256-7EA4EB0C-52E3-4337-885C-231F098F9B1D Q39137355-FB20264A-5BFD-4CD7-892C-B91661AE9A03 Q39148146-FDCC26C1-D882-48A3-966D-96D7A25FBD2D Q39282050-F2C2F196-C81B-4431-9CC5-F1D850A07895 Q39362339-FD44CD34-18CF-486B-8809-ED9C6BD8E2C3 Q39386374-A7AE22BA-0846-4401-A498-8E024BE4423D Q40052760-45833A48-68F5-4C39-AB5E-121A27835426 Q40114382-D8C1B9F8-8E98-40D8-BE53-9701932AEA4B Q40196691-ECADD60F-6AB8-4DC4-8DE0-BB87D5AEC3DA Q40533569-79DEC5C9-9AEE-4D51-BB27-1D1F2BFCA199 Q41926295-1A47BF40-ABF6-43DB-BD59-621A39BDA3E4 Q42315677-7DC429A1-E577-48CA-BA4F-4EF1F3497C10 Q46579323-0148DF67-1725-417C-B2AA-BE5514770832 Q47117982-951E9C5F-D8A1-4D64-96F4-98C7AD43B306 Q47389506-C138A3C9-AB8B-4718-9DB6-34F4264D8707 Q47552228-D9DA62E9-8C0C-4A94-8FCF-E853D533C3F8 Q47646796-E4835370-7EEC-4C4C-9531-59873D2B8F83 Q50048940-71583BD1-40BB-46A5-84C2-4BED0B610EBA

P2860

Glucocerebrosidase and Parkinson disease: Recent advances

http://www.wikidata.org/entity/Q27005669

description

2015 nî lūn-bûn

@nan

2015 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Glucocerebrosidase and Parkinson disease: Recent advances

@ast

Glucocerebrosidase and Parkinson disease: Recent advances

@en

Glucocerebrosidase and Parkinson disease: Recent advances

@nl

type

label

Glucocerebrosidase and Parkinson disease: Recent advances

@ast

Glucocerebrosidase and Parkinson disease: Recent advances

@en

Glucocerebrosidase and Parkinson disease: Recent advances

@nl

prefLabel

Glucocerebrosidase and Parkinson disease: Recent advances

@ast

Glucocerebrosidase and Parkinson disease: Recent advances

@en

Glucocerebrosidase and Parkinson disease: Recent advances

@nl

P1433

Q27005669-E2503DB4-155B-46F5-9222-743D78743072

P1476

Q27005669-2D3BA96A-0940-4A26-BCFD-3C55D31B53D3

P2093

Q27005669-6846EF71-8B8B-4DE8-A9A2-346F75C158A7

P2860

Q27005669-00CDC8C8-5343-4FCC-8CB7-C2E9EEB2F46C

Q27005669-040DC6AF-7510-447F-AC93-D145AD7BEE4A

Q27005669-09BF68A6-CA2F-40B5-9F70-BA5A00D8FB56

Q27005669-0B0FB999-64E6-455A-93E2-02B30C3D0187

Q27005669-14B50208-5ED7-43F3-8091-ECE3A7C7B9D9

Q27005669-17072B6F-C489-4F7F-996F-EDD28669D1A8

Q27005669-2185D233-5C50-4C4F-A7F0-1F245733D487

Q27005669-2A64DFB2-784D-4EA9-8F92-CC39DDB42584

Q27005669-2BAB4C35-E0E8-42F9-AFFF-2252947AE8A0

Q27005669-33B6A3DB-3EB6-41B9-9BC9-1ECB9919B715

P304

Q27005669-50F891D3-DF41-4B39-8D90-B80C804D9F2F

P31

Q27005669-17218EB7-8233-4B04-B67C-C219F5FEEA1F

P3181

Q27005669-E413B106-63CB-4D37-B475-FAD8F438C790

P356

Q27005669-34126554-1796-481A-97F3-4306B2114D4A

P407

Q27005669-8F4C9706-FAE6-4EE2-8CD1-B1C178B362F6

P433

Q27005669-656E7FF2-CC6A-4D0E-9BE3-E03C60AC4521

P478

Q27005669-4C9BE994-2405-4580-9E59-31C62837C5CD

P577

Q27005669-00E0CC89-FB53-4781-9C6D-F4242DD036EA

P698

Q27005669-142915CA-71C0-45A7-87D2-1A2A7DD9B01F

P921

Q27005669-2D58B573-5BD6-4ABD-BBD6-86EF058F1070

P932

Q27005669-EA36CFE0-1474-47EC-9166-670D1240DFA1

P3181

P356

J.MCN.2015.03.013

P1433

Molecular and Cellular Neuroscience

P1476

Glucocerebrosidase and Parkinson disease: Recent advances

@en

P2093

Anthony H.V. Schapira

http://www.w3.org/2001/XMLSchema#string

P2860

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease

Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models

Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and Stability

Chaperone-mediated autophagy markers in Parkinson disease brains

Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells

P304

37-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3614287

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.MCN.2015.03.013

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt A

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25802027

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4471139

http://www.w3.org/2001/XMLSchema#string